Frontier Biotech's HIV Drug Approved, First China-Developed HIV Treatment

Nanjing Frontier Biotech received CFDA approval for China use of albuvirtide, its novel long-acting treatment for HIV. Albuvirtide, a once-weekly injectable product, is the first China-developed HIV treatment to be approved for commercialization and also the first long-acting HIV treatment approved anywhere in the world. According to Frontier, albuvirtide has a novel mechanism of action that makes the molecule effective against common strains of HIV-1, including drug-resistant varieties. It believes the drug offers low frequency of dosing, high barriers to resistance and fewer side effects. More details....

Share this with colleagues:

More From BioPortfolio on "Frontier Biotech's HIV Drug Approved, First China-Developed HIV Treatment"